mouse

Potent endogenous neuropeptide S receptor (NPSR) agonist (EC50 = 3 nM). Induces mobilization of intracellular Ca2+. Increases locomotor activity and wakefulness in mice. Also reduces anxiety-like behavior in mice.

GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul

GFB-8438 是有效的TRPC5选择性抑制剂，对 hTRPC5 和 hTRPC4 的IC50分别为 0.18 和 0.29 μM。它对 TRPC6、其他 TRP 家族成员、NaV1.5 具有良好的选择性，对 hERG 通道的活性也有限。它对小鼠足细胞的保护作用。

BMS-813160 是CCR2/CCR5双重拮抗剂。有用于心血管的研究潜力。

Tomatidine hydrochloride (Tomatidine HCl) 是一种甾体生物碱，可防止肌肉萎缩并促进肌肉生长。它通过阻断 NF-κB 和JNK 信号发挥抗炎作用，可激活哺乳动物细胞或秀丽隐杆线虫中的自噬。

TAK-041 (NBI-1065846) 是一种选择性 GPR139激动剂，EC50为 22 nM，有用于精神分裂症阴性症状的研究潜力。

Anti-Mouse PD-1 Antibody (RMP1-14)是抗小鼠 PD-1 的 IgG2a 抗体抑制剂，可阻断 PD-1/PD-L1 信号传导。

Anti-Mouse PD-L1 Antibody (10F.9G2) 是抗小鼠 PD-L1 的 IgG 类抗体。

Orexin B, rat, mouse Acetate (Rat orexin B)(202801-92-1 free base) 是 Orexin 受体的内源性激动剂，对 OX1 和 OX2 的 Kis 分别为 420 和 36 nM。

Galanin (1-16), mouse, porcine, rat 是一种有效的甘丙肽受体激动剂，Kd 为 3 nM。

Enterostatin, human, mouse, rat acetate 是一种五肽，主要由分泌的胰腺前脂肪酶在肠道中形成。

Neuropeptide SF(mouse,rat) acetate (Neuropeptide SF(mouse,rat) acetate (230960-31-3 free base)) 是一种有效的神经肽 FF 受体激动剂，对 NPFF1 和 NPFF2 的 Ki 分别为 48.4 nM 和 12.1 nM。它增加了异源表达的酸感应离子通道 3 (ASIC3) 的持续电流的幅度。

PEN(mouse) acetate (proSAAS(221-242) Acetate) (1236955-25-1 Free base)是一种多肽衍生物。

Urotensin II, mouse acetate (9047-55-6 free base) 是孤儿 GPR14 或 SENR 的内源性配体。它是一种强效血管收缩剂。

C1qProtein (Mouse) 作为补体系统的一个亚基，具有辨识多种配体的能力，旨在维护免疫系统的平衡、促进组织的修复以及抵抗病原体。

Angiotensin I-13C6,15N (human, mouse, rat) TFA 是经过13C 和15N 标记的蛋白质,具体为Angiotensin I (human, mouse, rat) TFA 的同位素标记形式。此化合物作为angiotensin II的前体，在血管紧张素转化酶 (ACE) 的作用下被裂解, 产生angiotensin II。

Glb1 Mouse Pre-designed siRNA Set A 包括针对 Glb1 gene (Mouse) 的siRNA，以及阴性对照、阳性对照和FAM-labeled 阴性对照。

Kdm5d Mouse Pre-designed siRNA Set A 包括: 针对Kdm5d gene (Mouse)的siRNA，以及一个negative control、一个positive control和一个FAM-labeled negative control。

Ano10 Mouse Pre-designed siRNA Set A 包括三对针对 Ano10 (Mouse) 基因不同区域的 siRNA，以及阴性对照、FAM 标记阴性对照和阳性对照。

Ano5 Mouse Pre-designed siRNA Set A 包含三对针对 Ano5 (Mouse) 基因不同区域的 siRNA，以及阴性对照、FAM 标记阴性对照和阳性对照。

Anti-Mouse CD4 Antibody (2G5.D)是一种抗小鼠CD4抗体，广泛应用于生命科学领域的研究与实验。

Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004). Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2 References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004).

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

PAR2 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 2 (PAR2) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of mouse and rat PAR2. It also corresponds to residues 39-44 and 37-42 of the mouse and rat full-length sequences, respectively. PAR2 (1-6) induces relaxation in precontracted rat arteries in a concentration-dependent manner, an effect that can be reduced by the nitric oxide synthase inhibitor L-NNA . It inhibits keratinocyte growth in the presence and absence of growth factors. PAR2 (1-6) inhibits LPS-induced pulmonary neutrophil influx and increases in matrix metalloproteinase-2 (MMP-2) activity in mice.